MaxCyte (MXCT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
Call participants Chief Executive Officer — Maher Masoud Chief Financial Officer — Douglas J. Swirsky Chief Commercial Officer — Sean Menargas Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript Maher Masoud: Thank you, Erik. Good afternoon, everyone, thank you for joining MaxCyte, Inc.'s fourth quarter and full year 2025 earnings call. 2025 presented a challenging operating environment; it was also a year of meaningful progress for MaxCyte, Inc. We continue to sign new strategic platform licenses, SPLs as we call them, and support customers in advancing drugs to the clinic. We acquired SecurDx and successfully integrated the business into MaxCyte, Inc. We made meaningful changes to right-size spending and strategically improved our operations. And most recently, we launched a new product, the Xpert DTX, that will allow us to work with developers earlier in research and development discovery. Let me start by reviewing our financial r
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte (MXCT) had its price target lowered by Craig Hallum from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook [Seeking Alpha]Seeking Alpha
- MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- MaxCyte Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
MXCT
Earnings
- 3/24/26 - Miss
MXCT
Sec Filings
- 3/27/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/25/26 - Form 10-K
- MXCT's page on the SEC website